Search

Hutchison China MediTech Ltd ADR

Fechado

SetorSaúde

13.59 -4.36

Visão Geral

Variação de preço das ações

24h

Atual

Mín

13.1

Máximo

14.21

Indicadores-chave

By Trading Economics

Rendimento

-8.9M

-8M

Vendas

3.7M

139M

P/E

Médio do Setor

143.1

47.946

Margem de lucro

-5.724

Funcionários

1,790

EBITDA

18M

4M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+17.88% upside

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

575M

2.5B

Abertura anterior

17.95

Fecho anterior

13.59

Sentimento de Notícias

By Acuity

50%

50%

126 / 340 Ranking em Healthcare

Hutchison China MediTech Ltd ADR Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

8 de out. de 2026, 23:51 UTC

News

Brookdale Senior Living reported a 130 basis point increase in occupancy to 83.1% for Q3 2026, but shares declined in after-market hours.

8 de out. de 2026, 23:46 UTC

News

KKR shares are advancing as Refresco considers an IPO potentially valuing the firm at over $10 billion; KKR Capital Corp announced a $0.44 quarterly distribution.

8 de out. de 2026, 23:42 UTC

Social Media
News

Ginkgo Bioworks to provide in-kind access to its Boston lab for the National Science Foundation’s $1.5 billion X-Labs program supporting independent research teams.

8 de out. de 2026, 23:30 UTC

News

Pacira Biosciences shares declined in after-market hours following a downgrade by Jefferies to Hold, with a price target set at $36.

8 de out. de 2026, 23:30 UTC

News

Chipotle Mexican Grill Inc's stock advanced amid reports that Starbucks is considering a potential acquisition, with advisers enlisted for what could be a historic deal.

8 de out. de 2026, 23:30 UTC

News

Walt Disney Company is in talks with rival studios about its Infinity Vision format to compete with Imax, despite shares trading lower.

8 de out. de 2026, 23:20 UTC

News

Immersion Corp CEO Eric Singer acquired 41k shares for approximately $292.8K on October 7, according to a regulatory filing.

8 de out. de 2026, 23:15 UTC

News

Cleveland-Cliffs shares advanced in after-market trading as CEO Lourenco Goncalves discussed potential steelworker recalls tied to a Canada-U.S. trade deal.

8 de out. de 2026, 23:11 UTC

News

Abcellera Biologics to present Phase 1/2 data for investigational drug ABCL635 at The Menopause Society's Annual Meeting in October.

8 de out. de 2026, 23:10 UTC

News

Citigroup downgraded Universal Display Corp to Sell and lowered its price target to $71, contributing to investor caution ahead of earnings.

8 de out. de 2026, 23:10 UTC

News

JP Morgan maintains Underweight rating on Kennametal Inc and lowers price target to $30, contributing to a decline in the stock during after-market hours.

8 de out. de 2026, 23:10 UTC

News

Barclays initiates Equalweight coverage with $554 target.

8 de out. de 2026, 23:05 UTC

News

Boeing Co shares gained in after-market hours after Barclays initiated coverage with an Overweight rating and a price target of $300.

8 de out. de 2026, 23:05 UTC

News
Correlated Moves

HubSpot Inc. declines in after-market trading following a downgrade from JP Morgan, which lowered its rating to Neutral and price target to $240.

8 de out. de 2026, 23:05 UTC

News

Barclays initiates coverage on Joby Aviation with an Underweight rating and a price target of $4.00, contributing to recent declines in after-market trading.

8 de out. de 2026, 23:05 UTC

News

USD/CZK declines modestly following U.S. jobless claims data showing initial claims fell to 197k, indicating ongoing labor market strength amid broader economic concerns.

8 de out. de 2026, 23:01 UTC

Social Media
News
Event

Park Aerospace Corp reported second-quarter net sales of $20.79 million and net earnings of $4.53 million, exceeding expectations amid strong demand in aerospace sectors.

8 de out. de 2026, 23:01 UTC

News

Over 69% of Medicare Advantage members in high-rated plans for 2027

8 de out. de 2026, 23:01 UTC

Social Media
News

Alignment Healthcare's stock declined sharply after a downgrade of its largest California contract's Medicare Advantage Star Rating from 4 stars to 3.5 stars.

8 de out. de 2026, 23:01 UTC

News

JP Morgan maintains Neutral rating on Deere & Co, raises price target to $625, reflecting a cautious outlook on the company's performance.

8 de out. de 2026, 23:01 UTC

News

Moomoo launches 24/7 account deposits via Apple Pay and Google Pay through a partnership with Visa and Checkout.com to enhance user funding capabilities.

8 de out. de 2026, 23:01 UTC

News

Citigroup downgraded Xerox Holdings Corp to Sell and lowered its price target to $2.50, citing concerns over performance and market position.

8 de out. de 2026, 23:01 UTC

News
Social Media
Correlated Moves

Verizon shares fell sharply in after-hours trading, attributed to competitive pressures from SpaceX's spectrum license acquisition and AT&T's notable drop.

8 de out. de 2026, 23:01 UTC

Social Media
News

American Express faces regulatory scrutiny and agrees to a $350 million penalty for anti-money laundering deficiencies related to $13 billion in suspected activity.

8 de out. de 2026, 23:01 UTC

News

USD/ZAR declines as U.S. jobless claims show a four-week average of 198k, slightly down from 200.5k.

8 de out. de 2026, 23:01 UTC

Social Media
News

RTX Corp awarded a five-year contract worth up to $6.3 billion for Standard Missile-3 Block IB interceptors, announced by Raytheon.

8 de out. de 2026, 23:01 UTC

News

Humana's largest Medicare Advantage contract improved to 4 stars in the 2027 ratings, reinstating eligibility for federal quality bonus payments.

8 de out. de 2026, 23:01 UTC

News

DICK'S Sporting Goods faces a class action lawsuit for failing to disclose material information, with Kahn Swick & Foti, LLC urging affected shareholders to file by November 3, 2026.

8 de out. de 2026, 23:00 UTC

News

Citigroup maintains a Buy rating on Arista Networks and raises its price target to $248, according to a report published today.

8 de out. de 2026, 22:50 UTC

Social Media
News

Starbucks explored a potential acquisition of Chipotle, valued at $41 billion, but analysts express skepticism about the strategic rationale amid ongoing turnaround efforts.

Comparação entre Pares

Variação de preço

Hutchison China MediTech Ltd ADR Previsão

Preço-alvo

By TipRanks

17.88% parte superior

Previsão para 12 meses

Média 16.833 USD  17.88%

Máximo 18.5 USD

Mínimo 14 USD

Com base em 3 analistas de Wall Street que oferecem metas de preço de 12 meses para Hutchison China MediTech Ltd ADR - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

3 ratings

2

Comprar

1

Manter

0

Vender

Sentimento

By Acuity

126 / 340 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.